Center for Infectious Diseases Controlled Human Infection Models Malaria model Call for volunteers for research with a medicinal product

The study

​TB31F is an antibody which we believe may stop transmission (spreading) of malaria to a next person.

read more

The study

Malaria is the most common tropical infectious disease. Every year there are more than 200 million new cases and nearly half a million deaths. Most victims are African children. One way to protect against malaria is to sleep under an insecticide treated mosquito net. There are also medicines which can prevent and treat malaria. These have helped us to control malaria. However, mosquitoes are increasingly resistant to insecticides, and the parasites are gaining resistance to medication. Other tools are needed to control malaria. 

TB31F is an antibody which we believe may stop transmission (spreading) of malaria to a next person. TB31F has been tested in the laboratory and in animals but it has not been tested in humans before. In this study, TB31F will be tested in various dosages. The results of this research are important for the development of TB31F as a medicine to stop the spread of malaria.

TB31F study temporarily on hold due to COVID-19 measurements.

When we can resume this study we will organize new information sessions. Are you interested or would you like to receive more information? Register here

Who can participate?

We are looking for volunteers that

  • are healthy
  • are 18 - 35 years old
  • are residing in Nijmegen
  • have no history of malaria

Study timelines TB31F

In this Phase 1 study we want to evaluate the safety, tolerability, and pharmacokinetics and pharmacodynamics of monoclonal antibody TB31F in healthy malaria-naïve adults in the Netherlands.

  • This group started in February 2020 and is completed.

    Read more


    Research group 1

    Twenty healthy volunteers will participate in this study. There are four groups of five volunteers. Each group will receive a different dosage of TB31F because we want to test the safety and possible side effects of TB31F. We also want to study what dosage is necessary to block transmission of malaria parasites. You can choose in which group you want to be.

    Group 1 will receive the lowest dose of TB31F; group 2 will receive a slightly higher dose, and so on.


    Study period
    Start: This group has started in February 2020.
    The study lasts 12 weeks from the day of TB31F dosing. There are 11 visits in total. On the day of TB31F administration, you will have to stay at the hospital for the entire day. In the evening, you can go home but you will have to return to the hospital 8 more times for short follow-up visits.


    Compensation

    850 euro

  • Research group 2

    Twenty healthy volunteers will participate in this study. There are four groups of five volunteers. Each group will receive a different dosage of TB31F because we want to test the safety and possible side effects of TB31F. We also want to study what dosage is necessary to block transmission of malaria parasites. You can choose in which group you want to be. The first group will receive the lowest dose of TB31F; group 2 will receive a slightly higher dose, and so on.
     

    Study period

    Start: July 3, 2020
    The study lasts 12 weeks from the day of TB31F dosing. There are 11 visits in total. On the day of TB31F administration, you will have to stay at the hospital for the entire day. In the evening, you can go home but you will have to return to the hospital 8 more times for short follow-up visits.

     

    Compensation

    850 euro

  • Research group 3

    Twenty healthy volunteers will participate in this study. There are four groups of five volunteers. Each group will receive a different dosage of TB31F because we want to test the safety and possible side effects of TB31F. We also want to study what dosage is necessary to block transmission of malaria parasites. You can choose in which group you want to be. The first group will receive the lowest dose of TB31F; group 2 will receive a slightly higher dose, and so on.
     

    Study period

    Start: July 31, 2020
    The study lasts 12 weeks from the day of TB31F dosing. There are 11 visits in total. On the day of TB31F administration, you will have to stay at the hospital for the entire day. In the evening, you can go home but you will have to return to the hospital 8 more times for short follow-up visits.

     

    Compensation

    850 euro


  • Research group 4

    Twenty healthy volunteers will participate in this study. There are four groups of five volunteers. Each group will receive a different dosage of TB31F because we want to test the safety and possible side effects of TB31F. We also want to study what dosage is necessary to block transmission of malaria parasites. You can choose in which group you want to be. The first group will receive the lowest dose of TB31F; group 2 will receive a slightly higher dose, and so on.
     

    Study period

    Start: August 26, 2020
    The study lasts 12 weeks from the day of TB31F dosing. There are 11 visits in total. On the day of TB31F administration, you will have to stay at the hospital for the entire day. In the evening, you can go home but you will have to return to the hospital 8 more times for short follow-up visits.


    Compensation

    850 euro

Development of a malaria vaccine

Thanks to global attention to the spread of malaria, the number of malaria cases has dropped by nearly 50% over the past ten years. However, malaria continues to be responsible for a great deal of suffering and death. That is why our research focuses on the development effective vaccine.

More information


Contact

Saskia van der Boor MD
Clinical researcher

+31 (6) 1144 6136
+31 6 1539 9580
contact

Contact

Clinical researcher

+31 6 1144 6136
contact

Contact

Matthew McCall MD PhD
Project Lead

+31 6 1144 6136
contact